SCM
MNTA

Sigma Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Sigma Capital Management’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-170,000
Closed -$2.56M – 379
2013
Q2 		$2.56M Buy
+170,000
New +$2.24M 0.12% 164

Other funds holding MNTA

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sigma Capital Management's MNTA Position: Q3 2013 in Review

Sigma Capital Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2013, closing a stake of 170,000 shares — an estimated $2.56M sold.

Sigma Capital Management first reported a position in MNTA in Q2 2013 and held it in 1 quarter. The position peaked at $2.56M in Q2 2013. 126 funds tracked by Wall St. Rank hold MNTA as of Q3 2013.

  • Sigma Capital Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • Sigma Capital Management sold 170,000 Momenta Pharmaceuticals, Inc. shares in Q3 2013, an estimated $2.56M.
  • Sigma Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • Sigma Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $2.56M in Q2 2013.
  • 126 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2013.

Based on Sigma Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.